Autoantibody potential of cancer therapeutic monoclonal antibodies

International Journal of Cancer

Volumn 127, Issue 2, 2010, Pages 491-496

  McIntyre, John A ^a,b   Faulk, W Page ^a,c,d  

^a St Francis Hospital   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Faulk Pharmaceuticals Inc   (United States)

^d PURDUE UNIVERSITY   (United States)

Author keywords

Antiphospholipid; Autoimmunity; Oxidation; Reduction; Unmasked autoantibody

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; AUTOANTIBODY; BASILIXIMAB; BEVACIZUMAB; CD19 ANTIGEN; CETUXIMAB; DNA; GEMTUZUMAB OZOGAMICIN; GLYCOPHORIN A; HEMIN; HLA A29 ANTIGEN; HLA ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; INFLIXIMAB; MONOCLONAL ANTIBODY; PHOSPHOLIPID; POLYCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; HLA A ANTIGEN; HLA A29; HLA-A29;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CHIMERA; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; LYMPHOCYTE; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; BETA THALASSEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; METABOLISM; NEOPLASM;

ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; B-LYMPHOCYTES; BETA-THALASSEMIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; HEMIN; HLA-A ANTIGENS; HUMANS; IMMUNE TOLERANCE; NEOPLASMS; OXIDATION-REDUCTION;

EID: 77953694372     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25038     Document Type: Article

References (47)

1. Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells 2005;20:17-29.
2. Nalluri SH, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor Bevacizumab in cancer patients. JAMA 2008;300:2277-85.
3. Suntharalingam MR, Perry S, Ward SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-28. (Pubitemid 44343545)
4. Michaud GA, Salcius MF, Zhou R, Bangham R, Bonin J, Guo H, Snyder M, Predki PF, Schweitzer BI. Analyzing antibody specificity with whole proteome microarrays. Nat Biotechnol 2003;21:1509-12. (Pubitemid 37522714)
5. Predki PF, Mattoon D, Bangham R, Schweitzer B, Michaud GA. Protein microarrays: a new tool for profiling antibody cross-reactivity. Hum Antibodies 2005;14:7-15. (Pubitemid 43116918)
6. McIntyre JA, Wagenknecht DR, Faulk WP. Autoantibodies unmasked by redox reactions. J Autoimmun 2005;24:311-17.
7. McIntyre JA, Wagenknecht DR, Faulk WP. Redox-reactive autoantibodies: detection and physiological relevance. Autoimmun Rev 2006;5:76-83.
8. Merrill JT. Do antiphospholipid antibodies develop for a purpose? Curr Rheumatol Rep 2006;8:109-13.
9. McIntyre JA. The appearance and disappearance of antiphospholipid antibodies subsequent to oxidation-reduction reactions. Thromb Res 2004;114:579-87.
10. McIntyre JA, Wagenknecht DR, Faulk WP. Antiphospholipid antibodies: discovery, definitions, detection and disease. Prog Lipid Res 2003;42:176-237. (Pubitemid 36411692)
11. Wagenknecht DR, Sugi T, McIntyre JA. The evolution, evaluation and interpretation of antiphospholipid antibody assays. Clin Immunol Newsl 1995;15:28-38.
12. Chiu DT, Liu TZ. Free radical and oxidative damage in human blood cells. J Biomed Sci 1997;4:256-9.
13. Ando K, Ogawa K, Misaki S, Kikugawa K. Increased release of free Fe ions in human erythrocytes during aging in the circulation. Free Radic Res 2002;36:1079-84.
14. Phumala N, Porasuphatana S, Unchern S, Pootrakul P, Fucharoen S, Chantharaksri U. Hemin: a possible cause of oxidative stress in blood circulation of β-thalassemia/hemoglobin E disease. Free Radic Res 2003;37:129-35. (Pubitemid 36124339)
15. Burton C, Kacmarski R, jan-Mohamed R. Interstitial pneumonitits related to rituximab therapy. N Engl J Med 2003;348:2690-1.
16. Espinosa G, Cervera R, Font J, Asherson RA. The lung in the antiphospholipid syndrome. Ann Rheum Dis 2002;61:195-8.
17. Fukuno K, Tsurumi H, Ando N, Kanemura N, Goto H, Tanabashi S, Okamoto K, Moriwaki H. Late-onset neutropenia in patients treated with rituximab for non Hodgkin's lymphoma. Int J Hematol 2006;84:242-7.
18. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003;348:2691-4.
19. Boffa M-C, Piette J-C, eds. 9th International Symposium on antiphospholipid antibodies. J Autoimmun 2000;15:81-271.
20. McIntyre JA, Wagenknecht DR, Faulk WP. Redox-reactive autoantibodies. In: Shoenfeld Y, Gershwin ME, Meroni PL, eds. Autoantibodies. Oxford, UK: Elsevier, 2007. 47-53.
21. Liu X-Y, Pop LM, Vitetta ES. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008;222:9-27.
22. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-36.
23. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, Damaraju L, Schantz A, et al. Abciximab readministration: results of the ReoPro readministration registry. Circulation 2001;104:870-5.
24. Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004;136:393-401.
25. Caramaschi P, Ruzzenente O, Pieropan S, Volpe A, Carletto A, Bambara LM, Biasi D. Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titers after infliximab treatment: preliminary results. Rheumatol Int 2007;27:649-54.
26. Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun 2008;30:74-83.
27. Faulk WP, McIntyre JA. Autoimmunity reviews on redox signaling: prologue to autoimmunity forum. Autoimmun Rev 2008;7:515-17.
28. Hijmans W, Doniach D, Roitt IM, Holborow EJ. Serological overlap between lupus erythematosus, rheumatoid arthritis, and thyroid auto-immune disease. Br Med J 1961;2:909-14.
29. Conrad FJ, Rice JS, Cambier JC. Multiple paths to loss of anergy and gain of autoimmunity. Autoimmunity 2007;40:418-24.
30. Davies AJS. Immunological tolerance and the autoimmune response. Autoimmun Rev 2008;7:538-43.
31. Chou MY, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, Shaw PX, Choi J, Perkmann T, Bäckhed F, Miller YI, Hörkkö S, Corr M, et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009;119:1335-49.
32. Lutz HU, Binder CJ, Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol 2009;30:43-51.
33. Bobrovnik SA. Mechanisms for increasing the activity of polyreactive immunoglobulins in vivo. Ukr Biokhim Zh 1999;71:129-35.
34. Bobrovnik SA. Polyreactive immunoglobulins recognize hydrophobic parts of proteins. Ukr Biokhim Zh 2001;73:116-22.
35. Dimitrov JD, Lacroix-Desmazes S, Kaveri SV, Vassilev TL. Transition towards antigen-binding promiscuity of a monospecific antibody. Mol Immunol 2007;44:1854-63.
36. Kang J, Warren AS. Enthalpy-entropy compensation in the transition of a monospecific antibody towards antigen-binding promiscuity. Mol Immunol 2007;44:3623-24.
37. Dimitrov JD, Lacroix-Desmazes S, Kaveri SV, Vassilev TL. Insight into the mechanism of the acquired antibody autoreactivity. Autoimmun Rev 2008;7:410-14.
38. McIntyre JA, Faulk WP, eds. Redox and autoimmunity. Autoimmun Rev 2008;7:515-84.
39. Fellouse FA, Wiesmann C, Sachdev S, Sidhu S. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc Natl Acad Sci USA 2004;101:12467-73.
40. Tawfik DS, Chap R, Eshhar Z, Green BS. pH on-off switching of antibody-hapten binding site-specific chemical modification of tyrosine in antigen recognition. Protein Eng 1994;7:431-4.
41. Ghezzi P, Bonetto V. Redox proteomics: identification of oxidatively modified proteins. Proteomics 2003;3:1145-53.
42. Tian L, McClafferty H, Chen L, Shipston MJ. Reversible tyrosine protein phosphorylation regulates large conductance voltage- and calcium-activated potassium channels via cortactin. J Biol Chem 2008;283:3067-76.
43. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003;301:1374-7.
44. Casellas R, Zhang Q, Zheng NY, Mathias MD, Smith K, Wilson PC. Ig κ allelic inclusion is a consequence of receptor editing. J Exp Med 2007;204:153-60. (Pubitemid 46148765)
45. Yurasov S, Nussenzweig MC. Regulation of autoreactive antibodies. Curr Opin Rheumatol 2007;19:421-6.
46. + memory B cells. Immunity 2007;25:205-13.
47. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005;201:703-11. (Pubitemid 40395116)